Earnings Releases

Sphere 3D Corp. reported first fiscal quarter ended March 31, 2024 results: revenue $6.9 million, net income Net loss was $4.5 million, or a net loss of $0.27 per share, EPS a net loss of $0.27 per share.

“scale, today reported financial results for the first quarter of FY 2024 ended March 31, 2024. 2024 First Quarter Highlights and Recent Developments Revenue increased to $6.9 million during the quarter ended March 31, 2024. Sphere 3D mined 144.8 Bitcoin during the quarter ended March 31, 2024. Sphere 3D ended the quarter with 1.3 EH/s. CEO Comments “As we”

CareCloud, Inc. reported the three months ended March 31, 2024 results: revenue $26.0 million, net income ($241,000) or $(0.02) per share. Guidance reaffirmed.

“and health systems nationwide, today announced financial and operational results for the three months ended March 31, 2024. First Quarter 2024 Financial Highlights ● Revenue of $26.0 million, as compared to $30.0 million in Q1 2023 ● GAAP operating income of $129,000, as compared to operating loss of ($223,000) in Q1 2023 ● GAAP net loss of ($241,000) or $(0.02)”

Energous Corp reported the three months ended March 31, 2024 results: revenue approximately $0.1 million, net income approximately $(6.6) million, EPS $(1.11) per basic and diluted share.

“and provided an update on recent partnerships and company highlights. First Quarter 2024 Financial Results · Revenue for the three months ended March 31, 2024 of approximately $0.1 million versus $0.1 million in the 2023 period. · Costs and expenses for the three months ended March 31, 2024 totaled $6.7 million versus $6.4 million in the 2023 period. Total first”

Acumen Pharmaceuticals, Inc. reported first quarter of 2024 results: net income $14.9 million.

“Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended March 31, 2024.”

Bright Mountain Media, Inc. reported first quarter ended March 31, 2024 results: revenue $12.4 million, net income Net loss was $4.8 million.

“press release. --- EX-99.1 (EX-99.1) --- Bright Mountain Media, Inc Announces First Quarter 2024 Financial Results ■ First quarter revenue increased by $10.9 million to $12.4 million compared to $1.5 million for the first quarter of 2023. ■ First quarter gross margin increased by $2.6 million to $3.1 million compared to $528,000 for the first quarter of 2023.”

Ellington Credit Co reported quarter ended March 31, 2024 results: net income $4.0 million, or $0.20 per share, EPS $0.20 per share.

“On May 14, 2024, the Company issued a press release announcing its financial results for the quarter ended March 31, 2024.”

SYNLOGIC, INC. reported the quarter ended March 31, 2024 results: revenue $0.01 million, net income consolidated net loss of $31.6 million, or $2.60 per share, EPS $2.60 per share.

“transaction. First Quarter 2024 Financial Results As of March 31, 2024 Synlogic had cash, cash equivalents, and short-term marketable securities of $32.3 million. Revenue was $0.01 million for the three months ended March 31, 2024, compared to $0.2 million for the corresponding period in 2023. Revenue for the three months ended March 31, 2024 was related to a”

CV Sciences, Inc. reported for the quarter ended March 31, 2024 results: revenue $4.0 million.

“and products, today announced its financial results for the quarter ended March 31, 2024. First Quarter 2024 and Recent Financial and Operating Highlights • Generated revenue of $4.0 million for first quarter 2024 compared to $4.1 million for the first quarter 2023 and a sequential improvement from $3.8 million for the fourth quarter 2023; • Recognized gross margin”

Citius Pharmaceuticals, Inc. reported fiscal second quarter 2024 ended March 31, 2024 results: net income Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3, EPS ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024.

“Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update”

Contango Silver & Gold Inc. reported the three month period ended March 31, 2024 results: net income a net loss of $20.5 million or a loss of $2.14 per basic and diluted share, EPS $2.14 per basic and diluted share.

“The Company reported a net loss of $20.5 million or a loss of $2.14 per basic and diluted share for the three month period ended March 31, 2024”

OptiNose, Inc. reported quarter ended March 31, 2024 results: revenue $14.9 million, net income $14.1 million, EPS $0.12 per share. Guidance raised.

“First Quarter 2024 Financial Results Total revenues The Company reported $14.9 million in net revenue from sales of XHANCE during the three-month period ended March 31, 2024, an increase of 26% compared to $11.8 million during the three-month period ended March 31, 2023. Costs and expenses and net loss For the three-month period ended March 31, 2024, research and development expenses were $1.2 million and selling, general and administrative expenses were $20.5 million. The net loss for the period was $14.1 million, or $0.12 per share (basic and diluted).”

BOLLINGER INNOVATIONS, INC. reported financial results for three and six months ended March 31, 2024.

“On May 14, 2024, Mullen Automotive Inc. issued a press release announcing financial results for the three and six months ended March 31, 2024.”

NEUROONE MEDICAL TECHNOLOGIES Corp reported second quarter fiscal year 2024 ended March 31, 2024 results: revenue $1,377,000, net income $2.9 million.

“results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: ● Product revenue of $1,377,000 in Q2 2024, compared to $466,000 in Q2 2023 ● Raised an additional $2.0 million using the ATM Program in Q2 2024 Evo ® sEEG: ● Zimmer Biomet continued to expand into new”

TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2024 results: net income net loss of approximately $2.0 million, EPS $0.05 per share.

“As of March 31, 2024, Kintara had cash and cash equivalents of approximately $6.35 million. For the three months ended March 31, 2024, Kintara reported a net loss of approximately $2.0 million, or $0.05 per share, compared to a net loss of approximately $3.3 million, or $1.94 per share, for the three months ended March 31, 2023.”

ECA Marcellus Trust I reported the quarter ended March 31, 2024 results: EPS $0.021 per unit.

“ECA Marcellus Trust I (OTC Pink: ECTM) announced today that the Trust’s distribution for the quarter ended March 31, 2024, will be $0.021 per unit”

KALA BIO, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 14, 2024, KALA BIO, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a general business update.”

S&W Seed Co reported third quarter of fiscal year 2024 ended March 31, 2024 results: revenue $18.3 million, net income ($5.5) million, or ($0.13) per basic and diluted share. Guidance lowered.

“Seed Company (Nasdaq: SANW) today announced financial results for the three months ended March 31, 2024. Financial Highlights • Revenue for the third quarter of fiscal 2024 was $18.3 million, a 3.7% increase compared to the third quarter of fiscal 2023. Double Team TM sorghum revenue was $3.4 million in the third quarter of fiscal 2024 compared to $3.8 million in the”

Immunome Inc. reported first quarter ended March 31, 2024 results: net income net loss of $129.5 million, EPS basic and diluted net loss per share attributable to common stockholders of $2.51.

“Immunome, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024”

Vuzix Corp reported three months ended March 31, 2024 results: revenue $2.0 million, net income net loss of $10.0 million, EPS $0.16 cents per share.

“For the three months ended March 31, 2024, total revenues decreased by 52% to $2.0 million versus $4.2 million for the comparable period in 2023. The decrease in total revenues was due to lower product sales and specifically reduced unit sales of M400 smart glasses. Engineering services revenues were $0.2 million for the three months ended March 31, 2024 as compared to nil in the prior year’s quarter. There was an overall gross loss of $0.1 million for the three months ended March 31, 2024 as compared to a gross profit of $0.9 million or 21% of revenue for the same period in 2023. The loss was the result of lower revenues to absorb many of our relatively fixed manufacturing overhead costs as compared to the 2023 period. Research and Development expense was $2.7 million for the three months ended March 31, 2024, versus $3.1 million for the comparable 2023 period, a decrease of approximately 11%. This decrease was primarily due to reduced salary and benefits expenses. Selling and Marketi”

Unity Biotechnology, Inc. reported financial results for the first quarter ended March 31, 2024.

“On May 14, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.”

OptimizeRx Corp reported financial results for the first quarter ended March 31, 2024.

“On May 14, 2024, OptimizeRx Corporation issued a press release announcing its financial results for the first quarter ended March 31, 2024.”

InspireMD, Inc. reported first quarter ended March 31, 2024 results: revenue $1,511,000, net income $7,032,000, EPS $0.21 per basic and diluted share.

“For the first quarter of 2024, total revenue increased 22.0%, to $1,511,000, from $1,239,000 during the first quarter of 2023. This increase was predominantly driven by growth in existing markets . Gross profit for the first quarter of 2024 decreased by $81,000, or 21.6%, to $292,000, compared to a gross profit of $373,000 for the first quarter of 2023. This decrease resulted primarily from higher training costs of new hires to build capacity for anticipated increased volume requirements . Gross margin (gross profit as a percentage of revenue) decreased to 19.4% during the three months ended March 31, 2024, from 30.1% during the three months ended March 31, 2023. Total operating expenses for the first quarter of 2024 were $7,706,000, an increase of $2,952,000, or 62.1% compared to $4,754,000 for the first quarter of 2023. This increase was primarily due to higher share-based compensation resulting from the recognition of grants made during the second quarter of 2023 and the first quart”

Legacy Housing Corp reported first quarter ended March 31, 2024 results: revenue $43.2 million, net income $15.1 million, EPS $0.62.

““Legacy", NASDAQ: LEGH) today announced its financial results for the first quarter ended March 31, 2024. Financial Highlights § Net revenue for the first quarter of 2024 was $43.2 million, a decrease of 18.2% from the first quarter of 2023. § Income from operations for the first quarter of 2024 was $16.8 million, a decrease of 8.7% from the first quarter of”

TALPHERA, INC. reported the three months ended March 31, 2024 results: net income $4.0 million, EPS $0.16 per basic and diluted share.

“Talphera, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024”

Container Store Group, Inc. reported Full fiscal year ended March 30, 2024 results: revenue $847.8 million, EPS $2.09 per diluted share.

“Full-year consolidated net sales of $847.8 million, down 19.0% compared to fiscal 2022”

Container Store Group, Inc. reported fourth quarter and fiscal year ended March 30, 2024 results: revenue $206.0 million, net income $61.4 million, EPS $1.24 per diluted share.

“today announced its financial results for the fourth quarter and fiscal year 2023 ended March 30, 2024. For the fourth quarter of fiscal 2023: • Consolidated net sales were $206.0 million, down 20.7%, compared to the fourth quarter of fiscal 2022. Net sales in The Container Store retail business (“TCS”) were $195.3 million, down 20.4%. Elfa International AB”

Evoke Pharma Inc reported the first quarter ended March 31, 2024 results: revenue approximately $1.7 million, net income approximately $1.6 million, EPS $0.17 per share.

“physicians and the positive experiences shared by patients underscore the growing demand and trust in GIMOTI.” “In the first quarter of 2024, our net revenue of approximately $1.7 million faced marginal impacts from transient challenges, including a cyberattack on the largest U.S. medical claims processor and an increase in co-pay expenses covered by Evoke. The”

Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2024.

“Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024, a copy of which is furnished as Exhibit 99.1 to this report.”

DUOS TECHNOLOGIES GROUP, INC. reported first quarter Q1 2024 ended March 31, 2024 results: revenue $1.07 million, net income Net loss for Q1 2024 totaled $2.75 million. Guidance reaffirmed.

“Total revenues for Q1 2024 decreased 60% to $1.07 million”

Tracon Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $3.2 million.

“TRACON Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”

SELLAS Life Sciences Group, Inc. reported the first quarter ended March 31, 2024 results: net income $9.6 million, EPS $0.21.

“SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update”

FITLIFE BRANDS, INC. reported first quarter ended March 31, 2024 results: revenue $16.5 million, net income $2.2 million, EPS $0.47 and $0.43 respectively.

“products, today announced financial results for the first quarter ended March 31, 2024. Highlights for the first quarter ended March 31, 2024 include: ● Total revenue was $16.5 million, an increase of 54% compared to the first quarter of 2023. ● Online sales were $10.8 million, representing 65% of total revenue and an increase of 116% compared to the first”

ProMIS Neurosciences Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $3.6 million for the quarter ended March 31, 2024.

“Net loss was $3.6 million for the quarter ended March 31, 2024, compared to a net loss of $5.0 million for the same period in 2023.”

Ocugen, Inc. reported three months ended March 31, 2024 results: net income Total operating expenses for the three months ended March 31, 2024 were $13.2 million, EPS a $0.05 net loss per common share.

“Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.”

Ocugen, Inc. reported first quarter 2024 results: net income a $0.05 net loss per common share, EPS a $0.05 net loss per common share.

“Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.”

PRECIGEN, INC. reported financial results for first quarter 2024.

“Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 14, 2024, reporting its financial results for the quarter ended March 31, 2024.”

SOUNDTHINKING, INC. reported quarter ended March 31, 2024 results: revenue $25.4 million. Guidance reaffirmed.

“language in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 SoundThinking, Inc. Reports First Quarter 2024 Financial Results Revenues Increased 23% to $25.4 Million, Driven by New and Expanding Customer Subscriptions, and Contributions from SafePointe Company Reaffirms FY 2024 Revenue Guidance Range of $104.0 Million to $106.0 Million,”

TSS, Inc. reported first quarter ended March 31, 2024 results: revenue $15.9 million, net income $15,000 or $0.00 per share, EPS $0.00 per share.

“first quarter 2024 revenue of $15.9 million compared with $6.6 million in the first quarter of 2023. Procurement revenues were $11.6 million in the first quarter of 2024 compared to $1.7 million in the first quarter of 2023. ● Increased gross profits by $1 million or 61% compared to the first quarter of 2023 ● Improved Operating income by $918,000 to income of $253,000 in the first quarter of 2024 compared to an operating loss of $665,000 in the first quarter of 2023. ● Net income of $15,000 or $0.00 per share in the first quarter of 2024 compared to a net loss of $786,000 or $(0.04) per share in the first quarter of 2023.”

Comstock Holding Companies, Inc. reported the first quarter ended March 31, 2024 results: revenue $10,638, net income $910, EPS $0.09.

“success story throughout the remainder of 2024.” Key Performance Metrics ($ in thousands, except per share and portfolio data) Q1 2024 Q1 2023 Revenue $ 10,638 $ 10,275 Net income 910 754 Adjusted EBITDA $ 1,486 $ 1,626 Net income per share — diluted $ 0.09 $ 0.07 Managed Portfolio - # of assets 65 45”

Prestige Consumer Healthcare Inc. reported the fiscal year ended March 31, 2024 results: revenue $1,125.4 million, net income $209.3 million, EPS $4.17. Guidance initiated.

“Reported revenues for the fiscal year 2024 totaled $1,125.4 million compared to revenues of $1,127.7 million for the fiscal year 2023. Revenues increased 0.2% excluding the impact of foreign currency. Revenue performance for the fiscal year was driven by strong International OTC segment performance and strong Eye & Ear Care, GI, and Dermatological category sales in North America, partially offset by lower Women’s Health, Cough & Cold, and Analgesic category sales and the strategic exit of private label revenues. Reported net income for fiscal 2024 of $209.3 million compared to the prior year comparable period net loss of $82.3 million. Reported Fiscal 2024 diluted earnings per share was $4.17, compared to diluted loss per share of $1.65 in the prior year comparable period.”

Prestige Consumer Healthcare Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $277.0 million, net income $49.5 million, EPS $0.98. Guidance initiated.

“Reported revenues in the fourth quarter of fiscal 2024 of $277.0 million compared to $285.9 million in the fourth quarter of fiscal 2023. Revenues decreased 2.9% excluding the impact of foreign currency. The revenue decline in the quarter was attributable to the inability to supply customer orders late in the quarter in certain brands, the strategic exit of private label revenues, and a lower Women’s Health category, partially offset by growth in the International OTC segment. Reported net income for the fourth quarter of fiscal 2024 was $49.5 million versus the prior year comparable quarter’s net loss of $240.6 million. Diluted earnings per share of $0.98 for the fourth quarter of fiscal 2024 compared to a $4.83 diluted loss per share in the prior year comparable period.”

PARKS AMERICA, INC reported the six months ended March 31, 2024 results: revenue $3.86 million, net income $1.37 million, EPS ($0.02) per fully diluted share.

“Total revenues for the six months ended March 31, 2024, were $3.86 million, an increase of $118,981, or 3.2%, versus the comparable period ended April 2, 2023. Park revenues increased by $58,330 or 1.6%, to $3.73 million, and higher animal sales increased by $60,651, to $122,351. Reported park revenues for the Georgia park were down 4.0%. Reported park revenues for our Missouri and Texas parks increased 27.4% and 2.0%, respectively. On a pro forma basis, adjusting for the impact of the tornado related closure of our Georgia park for the final eight days of our 2023 fiscal second quarter, as well as a change in the accounting for online ticketing fees effective mid-January 2024, Missouri and Texas park revenue increased 29.6% and 3.7%, respectively, while Georgia park revenue decreased 14.1%. The Company reported a net loss of $1.37 million, or ($0.02) per fully diluted share, compared to $1.0 million or ($0.01) per fully diluted share, for the first six months of fiscal 2023.”

PARKS AMERICA, INC reported the fiscal quarter ended March 31, 2024 results: revenue $1.96 million, net income $1.0 million, EPS ($0.01) per fully diluted share.

“Total revenues for the fiscal quarter ended March 31, 2024, were $1.96 million, an increase of $82,735, or 4.4%, versus the comparable quarter ended April 2, 2024. Park revenues increased by $66,675 or 3.6%, to $1.92 million, and higher animal sales increased by $16,060, to $33,960. Reported park revenues for the Georgia park - our largest revenue generating property for the Company – were down 1.3%. Reported park revenues for our Missouri park increased 48.0%, while park revenues for our Texas park decreased 9.2%. On a pro forma basis, adjusting for the impact of the tornado related closure of our Georgia park for the final eight days of our 2023 fiscal second quarter, as well as the year-over-year park revenue impact of an improvement to our ticketing platform, Missouri park revenue increased 52.6%, while Georgia and Texas park revenue decreased 21.8% and 6.9%, respectively. The Company reported a net loss of $1.0 million, or ($0.01) per fully diluted share, compared to $846,139 or (”

Cellectar Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income The net loss attributable to common stockholders for the three months ended March 31, 2024, was ($21.6) million, or $(0., EPS $(0.74) per share.

“Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update”

Zoned Properties, Inc. reported first quarter ended March 31, 2024 results: revenue $837,052, net income $96,473, EPS $0.01.

“Revenues were $837,052 for the quarter ended March 31, 2024”

DYADIC INTERNATIONAL INC reported financial results for first quarter of 2024.

“On May 14, 2024, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended March 31, 2024.”

ALIMERA SCIENCES INC reported first quarter of 2024 results: revenue $23.0 million. Guidance reaffirmed.

“such a filing. ‎ 2 --- EX-99.1 (EX-99.1) --- Exhibit 99.1     FOR IMMEDIATE RELEASE   Alimera Sciences Reports First Quarter 202 4 Results  · Net Revenue up 70 % to $ 23 Million vs. Q1 202 3 · Global End User Demand Up 2 3 % vs. Q1 202 3 · Re iterates I mproved 2024 Net Revenue and Adjusted EBITDA G uidance  ATLANTA , May 14 , 202 4 -- Alimera Sciences,”

DNA X, Inc. reported the quarter ended March 31, 2024 results: revenue $16.8 million, net income $2.9 million.

“Sonim Technologies, Inc . (Nasdaq: SONM) , a leading provider of mobility solutions that include ultra-rugged and rugged phones, connected devices, consumer durable mobile devices, and accessories designed to provide extra protection for users that demand more durability in their work and everyday lives, reported financial results for the quarter ended March 31, 2024. First Quarter 2024 and Recent Highlights ● Net revenues increased by 25% sequentially, to $16.8 million ● GAAP net loss for the quarter was $2.9 million, compared to net loss of $1.4 million in the fourth quarter 2023 due to sales product mix.”

REED'S, INC. reported three months ended March 31, 2024 results: revenue $9.6 million, EPS $(0.16) per share. Guidance reaffirmed.

“of handcrafted, natural ginger beverages, is reporting financial results for the three months ended March 31, 2024. Q1 2024 Financial Highlights (vs. Q1 2023): ● Net sales were $9.6 million compared to $11.2 million. ● Gross profit increased 26% to $3.4 million, with gross margin up 1,140 bps to 35.6%. ● Delivery and handling costs were reduced by 29% to $3.01 per”

CHINA AUTOMOTIVE SYSTEMS INC/2 reported first quarter ended March 31, 2024 results: revenue $139.4 million, EPS $0.27.

“and systems supplier in China, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights ● Net sales were $139.4 million ● Gross profit increased by 11.6% to $24.1 million with a gross margin of 17.3%, compared with $21.6 million of gross profit and a 15.2% gross margin in the first quarter of”